These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1204 related items for PubMed ID: 30291192
1. Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, Kong G, Kumar AR, Thang SP, Eu P, Scalzo M, Murphy D, Williams S, Hicks RJ, Hofman MS. J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192 [Abstract] [Full Text] [Related]
3. Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy. Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, Suman S, Basu S, Das T, Banerjee S. Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495 [Abstract] [Full Text] [Related]
4. Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer. Götz TI, Lang EW, Prante O, Cordes M, Kuwert T, Ritt P, Ludwig B, Schmidkonz C. Nuklearmedizin; 2020 Sep; 59(5):365-374. PubMed ID: 32663888 [Abstract] [Full Text] [Related]
6. An Intrapatient Dosimetry Comparison of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer. Rinscheid A, Gäble A, Wienand G, Pfob C, Dierks A, Kircher M, Trepel M, Weckermann D, Lapa C, Bundschuh RA. J Nucl Med; 2023 Dec 01; 64(12):1918-1924. PubMed ID: 37770108 [Abstract] [Full Text] [Related]
7. Prediction of Response to 177Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC. Hohberg M, Reifegerst M, Drzezga A, Wild M, Schmidt M. J Nucl Med; 2023 Nov 01; 64(11):1758-1764. PubMed ID: 37652546 [Abstract] [Full Text] [Related]
8. Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer. Feuerecker B, Chantadisai M, Allmann A, Tauber R, Allmann J, Steinhelfer L, Rauscher I, Wurzer A, Wester HJ, Weber WA, d'Alessandria C, Eiber M. J Nucl Med; 2022 Jun 01; 63(6):833-839. PubMed ID: 34531260 [Abstract] [Full Text] [Related]
13. First-Strike Rapid Predictive Dosimetry and Dose Response for 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer. Kao YH, Falzone N, Pearson M, Sivaratnam D. J Nucl Med Technol; 2024 Sep 05; 52(3):212-218. PubMed ID: 38901967 [Abstract] [Full Text] [Related]
17. [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. Peters SMB, Hofferber R, Privé BM, de Bakker M, Gotthardt M, Janssen M, de Lange F, Muselaers CHJ, Mehra N, Witjes JA, Costa PF, Nagarajah J, Konijnenberg MW, Jentzen W. Eur J Nucl Med Mol Imaging; 2022 Mar 05; 49(4):1101-1112. PubMed ID: 34623453 [Abstract] [Full Text] [Related]
19. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Kabasakal L, AbuQbeitah M, Aygün A, Yeyin N, Ocak M, Demirci E, Toklu T. Eur J Nucl Med Mol Imaging; 2015 Dec 05; 42(13):1976-83. PubMed ID: 26227531 [Abstract] [Full Text] [Related]
20. [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma. Khawar A, Eppard E, Sinnes JP, Roesch F, Ahmadzadehfar H, Kürpig S, Meisenheimer M, Gaertner FC, Essler M, Bundschuh RA. Clin Nucl Med; 2018 May 05; 43(5):323-330. PubMed ID: 29485430 [Abstract] [Full Text] [Related] Page: [Next] [New Search]